Artificial Intelligence enters new phase of growth, as South Korea emerges as a key innovation frontrunner, new analysis from leading intellectual property firm, Marks & Clerk finds
- New analysis shows that whilst AI patent filings are still actively growing, the rate of this growth is slowing, a sign the market may now be maturing
- Number of EPO oppositions filed against patents rises again in 2021
- Computer vision technology sees growth in patent filings for fifth consecutive year
- Republic of Korea has the highest rate of AI applicants per capita
- The artificial intelligence (AI)…
A sample freezer failure is the worst case scenario for many laboratories. Do you have a process in place if your ULT freezer malfunctions?
It’s the worst case scenario for many laboratories and sample storage centres, your freezer has failed and your samples are ruined.
Whether it is due to the failure of a compressor, the power supply, or a temperature control issue, an ultra-low storage freezer failing can mean vital samples are spoiled within a matter of hours. With the sheer amount of user parts and variables in upright freezers it means that when they are employed for long term use,…
BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has chosen it to supply biosamples for the Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD) Project.
FTD, which…
Since COVID, the balance of power in biotech recruitment has shifted toward employees. What do companies need to know now about candidate motivation, and how can they adapt their proposition to win more talent?
It’s psychological …
It’s just got tougher for biotech companies – especially those at an early-stage where risk is greater – to access the talent essential to develop a successful business. Two factors, trends accelerated by COVID, are complicating the recruitment challenge. The first is straightforward and structural: there are more roles than people to fill them, making it a…
Cambridge, UK, 12th May 2022 / Domainex Ltd, a leading integrated medicines research services partner, is pleased to announce that Dr Scott Martin has been appointed Analytical and Bioanalytical Group Leader with immediate effect. His appointment will strengthen Domainex’s rapidly expanding team of international scientists and follows the announcement of Domainex’s purchase of over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays.
“I am delighted to join…
Click here to view the May 2022 edition of Dates for Your Diary
Seb Denby joins the team to support increased demand for Creative Places expertise across the UK
Friday 13th May 2022
Creative Places is delighted to welcome Seb Denby as Associate. An experienced Chartered Commercial Surveyor, Seb has over seven years’ experience of the agency, investment, acquisition and development markets both in Cambridge and across the UK.
Seb’s specific experience within the life science and R&D real estate sector…
Cambridge, UK 09 May 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted a European patent covering its unique Binary Assembly method for gene synthesis. The patent (EP 3688189 B1) further strengthens Evonetix’s IP portfolio and is a key milestone in the Company’s strategy to simplify gene synthesis for users and enable a new generation of in-lab DNA synthesis platforms.Evonetix’s novel semiconductor-based synthesis chip uses precise temperature control to manage the DNA synthesis cycle at…
A new partnership between PrecisionLife and Sano Genetics will help advance researchers’ understanding of the drivers of long COVID, identifying at-risk patients and potential drug targets.
PRESS RELEASE
OXFORD, UK May 11, 2022
PrecisionLife Limited, a global techbio company using its deep insights into disease biology and patient stratification to drive precision medicine in chronic diseases, is pleased to announce a partnership with Sano Genetics, a genetic research platform enabling patients to participate in ethical research projects, to advance understanding of the long-term effects of…
Cambridge, England, May 4th, 2022 – Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, today announced a strategic collaboration with Merck Healthcare, a division of Merck. Under the terms of the agreement, Merck and Amphista will work collaboratively to discover and develop small molecule protein degraders for an initial three targets in oncology and immunology indications. Amphista will receive an upfront payment, R&D funding and success-based milestone payments of up to €893.5 million ($1.0 billion…